Table IV.
Summary of the 9 cases who survived for >20 months following liver metastasis (LM).
| CRPa | Other metastatic sites | Survival after | |||||
|---|---|---|---|---|---|---|---|
| Case | Agea/gender | ECOG PSa | (mg/dl) | Grade | at the time of LM | Treatment for LM | LM (months) |
| 1 | 64/M | 0 | 0.3 | 3 | None | Sunitinib | 60.2 |
| 2 | 61/M | 1 | 0.6 | 3 | None | Hepatic recection, Nx | 55.1 |
| 3 | 71/F | NA | ND | 3 | Bone, lung | NA | 54.6 |
| 4 | 54/M | 0 | 0.6 | 2 | Lung, pancreas, stomach, duodenum | Interferon-α | 28.0 |
| 5 | 79/M | 0 | 5.9 | 2 | Lung | Interleukin-2 | 26.4 |
| 6 | 77/M | 1 | 0.3 | 3 | LR | SMANCS/lipiodol | 25.3 |
| 7 | 57/F | 0 | 28 | 3 | Lung, bone, pleura, LN, cerebellum | Interferon-α, sorafenib | 23.0 |
| 8 | 78/M | NA | ND | 3 | Lung | NA | 23.0 |
| 9 | 77/M | 1 | 0.6 | 3 | None | Hepatic recection | 22.0 |
a
At the time of LM presentation. ECOG PS, Eastern Cooperative Oncology Group performance status; CRP, C-reactive protein; M, male; F, female; Nx, nephrectomy; NA, not available; ND, not determined; LR, local reccurence; SMANCS, stylene-maleic acid neocarzinostatin; LN, lymph node.